Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on developing treatments for RAS/MAPK pathway-driven cancers, has announced positive outcomes from the dose escalation phase of its Phase 1/2 trial of GFH375, also known as VS-7375 in the United States. As reported, the trial, conducted by GenFleet Therapeutics, demonstrated an overall response rate $(ORR.AU)$ of 52% in patients with pancreatic ductal adenocarcinoma (PDAC) and 42% in those with non-small cell lung cancer (NSCLC) as of May 16, 2025. These results were disclosed during a rapid oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago. Verastem plans to commence a Phase 1/2a study of VS-7375 in the U.S. with potential global expansion, focusing on patients with advanced KRAS G12D mutant solid tumors. This study will assess the safety and efficacy of VS-7375, both as a standalone therapy and in combination with other treatments. The company announced this development and further details will be discussed during an investor webcast scheduled for June 2, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.